ClinicalTrials.gg
Active, not recruitingNCT06514807Updated Dec 19, 2024

A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

A Phase 3 interventional study of Ropeginterferon alfa-2b (BESREMi®) in Essential Thrombocythaemia, sponsored by AOP Orphan Pharmaceuticals AG. Active, not recruiting at 36 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by AOP Orphan Pharmaceuticals AG · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2023, registered Jul 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
117
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Thrombocythemia, Essential with a site in Germany — 3 open to participants now, 10 under way, 4 of them phase 3. Thrombocythemia, Essential · Germany.

Planned enrollment
13th of 23
117 · median 120
Started
2023
with 2 others
Phase 3
8 of 28
1 open now
Registered
25th of 28
by date
Lead sponsor
2 of 28
AOP Orphan Pharmaceuticals AG

Among the 28 studies in Thrombocythemia, Essential with a site in Germany, this one is the 13th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 in phase 3, and was the 25th registered.

Thrombocythemia, Essential

230 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.

Browse Thrombocythemia, Essential studies →

Open to participants now

3 of the 28 studies in Thrombocythemia, Essential with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Thrombocythemia, Essential with a site in Germany, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of ropeginterferon alfa-2b in patients with ET who need cytoreductive treatment but are intolerant or refractory to, and/or ineligible for cytoreductive treatments approved and available for the treatment of ET (i.e., HU, ANA, BUS, and PB, when they are available and approved for ET treatment).

Ropeginterferon alfa-2b is currently the only interferon authorised as a cytoreductive treatment of a myeloproliferative neoplasm (MPN), and the long-term treatment data from its comprehensive clinical development program show its efficacy in the induction of haematologic remission, resolution of disease-associated symptoms, disease-modifying effect, as well as its favourable safety profile (Gisslinger et al., 2020; Kiladjian et al. 2022).

Available clinical data and experience show that ropeginterferon alfa-2b normalises various haematological parameters, including platelets. In addition, suppression of the malignant clone causing ET may be achieved, at least after long-term treatment, which is expected to possibly defer the onset of, or avoid long-term sequelae of ET.

03

Conditions studied

  • Essential Thrombocythaemia

Keywords

  • Ropeginterferon alfa-2b
  • essential thrombocythaemia
  • intolerant to cytoreductive treatment
  • refractory to cytoreductive treatment
  • not eligible for other cytoreductive treatments
  • JAK2
  • CALR
  • MPL mutation status
  • BESREMi
  • Thrombocythaemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained from the patient and ability for the patient to comply with the requirements of the study.
  2. Male or female patients ≥ 18 years old
  3. Patients diagnosed with ET according to the World Health Organization (WHO) 2016 criteria (with a bone marrow test result not more than 5 years old) who need cytoreductive treatment but are intolerant or to, and/or ineligible for all cytoreductive treatments approved for the treatment of ET (i.e., HU, ANA, BUS, and PB1).

    Patients resistant/intolerant to HU must have documented resistance/intolerance as defined by modified ELN criteria (Barosi, et al. 2007), whereby at least one of the following criteria is met:

    1. count >600 x 109/L at ≥2 g/day (or ≥2.5 g/day if patient body weight >80 kg) or maximally tolerated dose if \<2 g/day or at maximum dose per local practice after at least 3 months of HU
    2. Platelet count >400 x 109/L and WBC count \<2.5 x 109/L at any dose and any duration of HU
    3. Platelet count >400 x 109/L and (Hb) \<10 g/dL at any dose and any duration of HU
    4. Presence of HU-related toxicities at any dose and any duration of therapy (e.g., leg ulcers, mucocutaneous manifestations, pneumonitis, or HU-related fever)

    Patients resistant/intolerant to ANA, BUS, or PB must meet at least one of the following criteria:

    1. Patient designated as non-responder according to the primary efficacy endpoint of this protocol (modified ELN criteria) after at least 3 months of treatment with the recommended dosing defined in SmPC or local practice
    2. Presence of treatment-related toxicities at any dose and any duration of therapy Patients ineligible for HU: with as defined by locally available HU SmPC or designated as such by investigator due to benefit-risk concerns (e.g., patients with toxic ranges of myelosuppression, teratogenic/leukaemogenic/carcinogenic concerns, male patients of reproductive, age not willing or unable to use an effective method of ). Patients ineligible for ANA: with contraindication as defined by locally available ANA SmPC or designated as such by investigator due to benefit-risk concerns (e.g., cardiovascular risk factors, including heart failure, , the risk for progression to myelofibrosis). Patient ineligible for BUS and PB (in countries where BUS or PB is available and approved for treatment of ET): with contraindication as defined by locally available BUS/PB SmPC or designated as such by investigator due to benefit-risk concerns (e.g., teratogenic/leukaemogenic/carcinogenic concerns, male patients of reproductive age not willing or unable to use an effective method of contraception).
  4. If a patient received prior cytoreductive treatment for ET, the between the last dose of treatment and the first dose of the study drug must be at least 14 days, or longer. (If the washout period not completed at time of first patients screening, washout may be done after obtaining ICF during the 28-day screening phase).
  5. Interferon treatment-naïve
  6. Adequate hepatic function defined as ≤1.5 x upper limit normal (), ≤1.5 x ULN, albumin >3.5 g/dL, ≤2.0 x ULN, aspartate aminotransferase ≤2.0 x ULN at screening.
  7. Hospital Anxiety and Depression Scale (HADS) score 0-7 on both subscales.
  8. Patient with HADS score of 8-10 inclusive on either, or both, of the subscales may be eligible following psychiatric assessment that excludes clinical significance of the observed symptoms in the context of potential treatment with an interferon alfa.

Exclusion criteria

Exclusion Criteria:

  1. Any patient requiring a legally authorised representative
  2. Any to IFN-α or to any of the drug
  3. Pre-existing thyroid disease, if not in remission or not controlled with conventional treatment
  4. Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation or suicide attempt
  5. Severe cardiovascular disease (i.e., uncontrolled hypertension, congestive heart failure (≥ class 2), serious cardiac arrhythmia, significant coronary artery stenosis, unstable angina) or recent stroke or myocardial infarction or pulmonary hypertension
  6. Patients with diabetes mellitus that cannot be effectively controlled by medicinal products
  7. History or presence of disease (excluding well-controlled Hashimoto's disease)
  8. transplant recipients
  9. Concomitant treatment with telbivudine
  10. Decompensated cirrhosis of the liver ( B or C)
  11. End stage renal disease ( \<15 mL/min)
  12. Symptomatic splenomegaly (per the investigator's judgement)
  13. Patients with any other significant medical conditions that, in the opinion of the Investigator, would compromise the results of the study or may impair compliance with the requirements of the protocol, including but not limited to:

    1. History of any within 5 years (except Stage 0 chronic lymphocytic leukaemia, basal cell, squamous cell, and superficial melanoma)
    2. Infections with systemic manifestations (e.g., bacterial, fungal, or [HIV], except [HBV] and/or [HCV], at screening)
    3. Evidence of severe retinopathy (e.g., cytomegalovirus retinitis, macular degeneration) or ophthalmological disorder (due to diabetes mellitus or hypertension)
    4. History of alcohol or drug abuse within the last year
  14. Use of any drug \<4 weeks prior to the first dose of study drug, or ongoing effects/symptoms due to prior administration of any investigational agent
  15. HADS score of 11 or higher on either, or both, of the subscales, and /or development or worsening of the clinically significant depression or suicidal thoughts
  16. Pregnant patients or breastfeeding patients or females of not willing to comply with requirements as described in Section 16.1.4
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
117 participants (estimated)

Study arms

  • Experimental
    Ropeginterferon alfa-2b (tradename BESREMi®)

    Ropeginterferon alfa-2b (tradename BESREMi®) 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen. Ropeginterferon alfa-2b will be administered subcutaneously every 2 weeks at a dose of 125 µg / 250 µg / 500 µg per injection (depends on the optimal disease response) for up to 36 months of treatment.

    Drug: Ropeginterferon alfa-2b (BESREMi®)

Interventions

06

What researchers measure

Primary outcomes

  1. Durable (for at least 3 months) peripheral blood count remission

    PLTs ≤400 x 109/L AND WBC \<10 x 109/L

    Time frame: At month 12

  2. Absence of haemorrhagic or thrombotic events and absence of disease progression*

    \*Progression is defined as conversion from asymptomatic to symptomatic splenomegaly or clinically relevant progression of spleen size at the Investigator's discretion, respectively.

    Time frame: At month 12

  3. Absence or Non-progression* in disease-related signs

    \*Progression is defined as conversion from asymptomatic to symptomatic splenomegaly or clinically relevant progression of spleen size at the Investigator's discretion, respectively.

    Time frame: At month 12

  4. Durable (for at least 3 months) large symptoms improvement or maintenance of non-progression based on the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)#

    # Large symptoms improvement for ET patients is defined as follows: * Baseline TSS ≥20: 10-points reduction in TSS * Baseline TSS 15-19, inclusive: 5-points reduction in TSS * Baseline TSS 10-14, inclusive: TSS decreases to ≤10 * Baseline TSS \<10: TSS stays \<10

    Time frame: At month 12

Secondary outcomes

  1. Response at month 9, 18, 24, 30 and 36

    Time frame: Month 9, 18, 24, 30 and 36

  2. Longitudinal changes in the ELN response rates over 12 months

    Time frame: up to 36 months

  3. Time to first response (as defined by ELN criteria)

    Time frame: up to 36 months

  4. Duration of first response (as defined by ELN criteria)

    Time frame: up to 36 months

  5. Duration of first durable response (as defined by ELN criteria)

    Time frame: up to 36 months

  6. Time to first peripheral blood count remission response

    Time frame: up to 36 months

  7. Duration of first durable peripheral blood count remission response

    Time frame: up to 36 months

  8. Occurrence of thromboembolic and bleeding events response

    Time frame: up to 36 months

  9. Occurrence of disease progression response

    Time frame: up to 36 months

  10. Symptomatic improvement assessed by EQ-5D-5L questionnaire response

    Time frame: up to 36 months

  11. Symptomatic improvement assessed by the 10-item MPN-SAF TSS

    Time frame: up to 36 months

  12. Change in inflammation markers over time

    Time frame: up to 36 months

  13. Change in CALR, MPL, or JAK2 allelic burden over time

    Time frame: up to 36 months

Other outcomes

  1. Safety endpoints

    Adverse events (AEs), according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0)

    Time frame: up to 36 months

07

Study locations

36 sites
  • University Hospital Graz, Department of Internal Medicine, Clinical Department of Hematology
    Graz, Styria 8036, Austria
  • Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)
    Innsbruck, Tyrol 6020, Austria
  • Ordensklinikum Linz GmbH Elisabethinen Hospital, Department of Internal Medicine I - Hemato-Oncology
    Linz, Upper Austria 4020, Austria
  • Medical University Vienna, Department of Internal Medicine I, Clinical Department of Hematology and Hemostaseology
    Vienna, Austria
  • University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology
    Brno, 625 00, Czechia
  • University Hospital Kralovske Vinohrady, Clinic of Internal Hematology
    Prague, 10000, Czechia
  • Saint-Louis Hospital, Department of Adult Hematology
    Paris, 75010, France
  • Bordeaux University Hospital, Haut-Leveque Hospital
    Pessac, 33600, France
  • Centre Hospitalier Universitaire De Poitiers
    Poitiers, 86000, France
  • University Hospital Aachen, Clinic of Oncology, Hematology and Stem Cell Transplantation (Medical Clinic IV)
    Aachen, 52074, Germany
  • University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology
    Halle, 06120, Germany
  • Hannover Medical School, Clinic for haematology, haemostaseology, oncology and stem cell transplantation
    Hannover, 30625, Germany
  • University Hospital Mannheim, Medical Clinic III, Hematology and Internistic Oncology
    Mannheim, 68167, Germany
  • Johannes Wesling Hospital Minden, Department of Oncology and Hematology
    Minden, 32429, Germany
  • University Hospital Ulm, Center for Internal Medicine, Clinic of Internal Medicine III, Department of Hematology, Oncology, Rheumatology, Infectious Diseases
    Ulm, 89081, Germany
  • General Hospital of Athens Alexandra, Therapeutic Clinic, Department of Therapeutics
    Athens, 11528, Greece
  • University General Hospital "Attikon"
    Athens, PC 12462, Greece
  • Semmelweis University, Department of Internal Medicine and Haematology, Division of Hematology
    Budapest, H-1088, Hungary
  • University of Debrecen Clinical Center, Clinic of Internal Medicine, Department of Hematology
    Debrecen, 4032, Hungary
  • Polyclinic S. Orsola-Malpighi
    Bologna, 40138, Italy
  • Careggi University Hospital, Department of Hematology
    Florence, 50134, Italy
  • Umberto I Polyclinic of Rome
    Rome, 00161, Italy
  • University Polyclinic Foundation "Agostino Gemelli" - IRCCS, Service of Hematology
    Rome, 00168, Italy
  • University Hospital City of Health and Science of Turin - Hospital Molinette, Complex Structure of Hematology - U
    Turin, 10126, Italy
  • University Teaching Centre, Hematology and Transplantology Clinic
    Gdansk, 80-952, Poland
  • Pratia Oncology Katowice
    Katowice, 40-519, Poland
  • Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department
    Kraków, 31-501, Poland
  • Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz, Department of Hematooncology with Subdivision of Daytime Chemotherapy
    Łódź, 93-513, Poland
  • Onco Card Srl
    Brasov, 500052, Romania
  • "Prof. Dr. Ion Chiricuta" Institute of Oncology, Hematology Department
    Cluj-Napoca, 400015, Romania
  • Fundeni Clinical Institute, Center for Hematology and Bone Marrow Transplantation
    Crisan, 022328, Romania
  • Iasi Regional Institute of Oncology, Department of Hematology
    Iasi, 700483, Romania
  • University Hospital Germans Trias i Pujol
    Badalona, 08916, Spain
  • Hospital Clinic of Barcelona, Department of Hematology
    Barcelona, 08036, Spain
  • University Hospital Ramon y Cajal, Hematology Service
    Madrid, 28034, Spain
  • Morales Meseguer University General Hospital
    Murcia, 30008, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Mar 2028, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2024
First posted
Jul 23, 2024
StartActual
Dec 4, 2023
Primary completionEst.
Mar 15, 2028
CompletionEst.
Mar 15, 2028
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06514807
Lead sponsor
AOP Orphan Pharmaceuticals AG
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Dec 4, 2023
Primary completion
Mar 15, 2028 (estimated)
Completion
Mar 15, 2028 (estimated)
Last update
Dec 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropeginterferon alfa-2b

Start the discussion